查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601186

药品开发和受託製造市场：按服务、开发阶段和最终用户划分 - 2025 年至 2030 年全球预测

Pharmaceutical Contract Development & Manufacturing Market by Service, Development Stage, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年合约药品研发受託製造市场规模为1,257.3亿美元，预计2024年将达1,362.7亿美元，复合年增长率为8.46%，2030年将达2,220.4亿美元。

受託製造（CDMO）产业是医疗供应链的重要组成部分，为各种规模的製药公司提供药物开发、製造和包装等基本服务。这项需求源自于製药公司越来越需要专注于其核心竞争力，同时利用 CDMO 专业知识来简化产品创新并更有效地将药物推向市场。 CDMO 的范围涵盖整个药物製造生命週期，包括合成、配方、临床测试和商业生产。主要的最终用途领域包括大型製药公司、生物技术公司和学名药製造商。市场开拓受到生技药品和生物相似药需求增加、缩短药物开发时间的压力以及需要专业製造能力的外包增加等因素的推动。最近的机会包括扩大我们在细胞和基因治疗方面的能力，利用人工智慧来优化流程，以及建立策略伙伴关係以增强我们的服务产品。然而，他们面临严格的监管要求、高昂的初始投资成本以及影响生产计划的供应链中断等挑战。

主要市场统计
基准年[2023] 1257.3亿美元
预测年份 [2024] 1362.7亿美元
预测年份 [2030] 2220.4亿美元
复合年增长率（%） 8.46%

为了抓住新的资料，CDMO 专注于扩大其在个人化医疗和再生疗法方面的产品，投资于连续加工和 3D 列印等尖端製造技术，并建立强大的产品组合以提高决策能力。此外，与技术提供者合作可以帮助克服该行业面临的一些技术挑战。先进製造基础设施和维持遵守全球监管标准所需的高资本支出通常是有限的。 CDMO 市场本质上是动态的，其特点是技术快速进步和不断变化的客户需求。对研发和创新的持续投资，加上策略伙伴关係关係，使 CDMO 能够实现持续成长，同时克服现有和新的挑战。

市场动态：揭示快速发展的合约药物开发和受託製造市场的关键市场见解

由于供需的动态相互作用，药物开发和受託製造市场正在经历转型。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 对学名药和生物治疗的需求不断增长
    • 加大医药研发投入
    • CDMO数量增加以及CDMO加大对先进製造技术的投资
  • 市场限制因素
    • 采用序列化
  • 市场机会
    • 对核子医学和专科药物的日益关注
    • 对细胞和基因治疗的需求不断增加
  • 市场问题
    • 各国的贸易政策有所不同

波特五力：驾驭药物开发与受託製造市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解药物开发和受託製造市场的外部影响

外部宏观环境因素在塑造药物开发和受託製造市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解药物开发和受託製造市场的竞争状况

对药物开发和受託製造市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：药物开发与受託製造市场中的供应商绩效评估

FPNV定位矩阵是评估药物开发和受託製造市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：规划药物开发和受託製造市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，药物开发和受託製造市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对学名药和生物疗法的需求增加
      • 加大医药研发投入
      • CDMO数量增加以及CDMO加大对先进製造技术的投资
    • 抑制因素
      • 采用序列化
    • 机会
      • 对核子医学和专科药物的关注增加
      • 对细胞和基因治疗的需求不断增长
    • 任务
      • 国家间贸易政策的多样性
  • 市场区隔分析
    • 服务：最终用户更多采用生物製药製造服务，以遵守严格的监管标准
    • 最终用户：大型製药公司广泛采用製药 CDMO 服务来管理复杂的药物开发
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 药品开发与受託製造市场：依服务分类

  • 介绍
  • 生物製药製造服务
    • 生技药品原料药生产服务
    • 生物製品FDF製造服务
  • 药物开发服务
  • 药品製造服务
    • 医药原料药製造
      • 胶囊製造服务
      • 口服液製造服务
      • 注射剂/注射製造服务
      • 平板电脑製造服务
    • 製药FDF製造
  • 二次包装服务

第七章 药物开发与受託製造市场：依开发阶段划分

  • 介绍
  • I期临床试验
  • II期临床试验
  • III期临床试验
  • IV期临床试验
  • 临床前

第八章 药物开发和受託製造市场：按最终用户分类

  • 介绍
  • 生技公司
  • 学名药公司
  • 製药公司
    • 大型製药公司
    • 特种药品
  • 中小型製药公司

第九章 北美和南美的药物开发和受託製造市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章 亚太药物开发与受託製造市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的药品开发和受託製造市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • AGC Biologics 和 BioConnection 合作提供端到端生物製药开发和製造解决方案，以提高效率并加快上市时间
    • Kuhne Holding AG 从 BC Partners 收购 Aenova Group 多数股权，利用资源促进成长和创新
    • Alcami 宣布收购总部位于西海岸的 Pacific Pharmaceutical Services
    • Piramal Pharma 投资 100 亿印度卢比扩大业务
    • eXmoor Pharma 开设 GMP 设施，成为细胞和基因治疗领域的全方位服务 CDMO 合作伙伴
  • 战略分析和建议

公司名单

  • AbbVie, Inc.
  • Acino International AG
  • Aenova Holding GmbH
  • Akums Drugs& Pharmaceuticals Ltd
  • Almac Group Limited
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Curia Global, Inc.
  • Danaher Corporation
  • Delwis Healthcare Pvt. Ltd.
  • Evonik Industries AG
  • Fabbrica Italiana Sintetici SpA
  • Famar Health Care Services
  • FUJIFILM Diosynth BIoTechnologies USA, Inc.
  • Gerresheimer AG
  • Grifols SA
  • Hikal Ltd
  • Hovione
  • Jubilant Pharmova Limited
  • Lonza Group AG
  • Pfizer Inc.
  • Porton Pharma Solutions Ltd.
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Siegfried AG
  • The Fareva Group
  • Thermo Fisher Scientific Inc.
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • WuXi Biologics Co., Ltd.
Product Code: MRR-4316E4E8930E

The Pharmaceutical Contract Development & Manufacturing Market was valued at USD 125.73 billion in 2023, expected to reach USD 136.27 billion in 2024, and is projected to grow at a CAGR of 8.46%, to USD 222.04 billion by 2030.

The pharmaceutical contract development and manufacturing (CDMO) industry serves as a critical component in the healthcare supply chain, providing essential services such as drug development, manufacturing, and packaging to pharmaceutical companies of all sizes. Its necessity stems from the increasing need for pharmaceutical firms to focus on their core competencies while leveraging CDMO expertise to streamline product innovation and bring drugs to market more efficiently. The application scope of CDMOs spans the entire drug production lifecycle, including synthesis, formulation, clinical trials, and commercial manufacturing. Key end-use segments include large pharma companies, biotech firms, and generic drug producers. Market growth is fueled by factors such as rising demand for biologics and biosimilars, the pressure to reduce drug development time, and an increase in outsourcing activities driven by the need for specialized manufacturing capabilities. Recent opportunities include expanding capabilities in cell and gene therapies, leveraging artificial intelligence for process optimization, and forming strategic partnerships to enhance service offerings. However, the market faces challenges such as stringent regulatory requirements, high initial investment costs, and supply chain disruptions impacting production timelines.

KEY MARKET STATISTICS
Base Year [2023] USD 125.73 billion
Estimated Year [2024] USD 136.27 billion
Forecast Year [2030] USD 222.04 billion
CAGR (%) 8.46%

To capture emerging opportunities, CDMOs should focus on expanding their offerings in personalized medicine and regenerative therapies, invest in cutting-edge manufacturing technologies like continuous processing and 3D printing, and develop robust data analytics capabilities for improved decision-making. Moreover, forming alliances with technology providers can help overcome some technological challenges faced by the sector. Limitations are often related to the high capital expenditure required for advanced manufacturing infrastructure and maintaining compliance with global regulatory standards. The CDMO market is inherently dynamic, characterized by rapid technological advancements and evolving client demands, making it critical for companies to remain agile and forward-thinking. Continuous investment in R&D and innovation, paired with strategic partnerships, can position CDMOs for sustained growth while navigating existing and emerging challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmaceutical Contract Development & Manufacturing Market

The Pharmaceutical Contract Development & Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Demand for Generics and Biological Therapies
    • Increasing Investments in Pharmaceutical R&D
    • Increasing Number of CDMOs and Rising Investments in Advanced Manufacturing Technologies by CDMOs
  • Market Restraints
    • Introduction of Serialization
  • Market Opportunities
    • Increasing Focus on Nuclear Medicine and Specialty Drugs
    • Growing need for Cell and Gene Therapies
  • Market Challenges
    • Variable Trade Policies Between Countries

Porter's Five Forces: A Strategic Tool for Navigating the Pharmaceutical Contract Development & Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmaceutical Contract Development & Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmaceutical Contract Development & Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmaceutical Contract Development & Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmaceutical Contract Development & Manufacturing Market

A detailed market share analysis in the Pharmaceutical Contract Development & Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmaceutical Contract Development & Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmaceutical Contract Development & Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pharmaceutical Contract Development & Manufacturing Market

A strategic analysis of the Pharmaceutical Contract Development & Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Contract Development & Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Acino International AG, Aenova Holding GmbH, Akums Drugs& Pharmaceuticals Ltd, Almac Group Limited, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Curia Global, Inc., Danaher Corporation, Delwis Healthcare Pvt. Ltd., Evonik Industries AG, Fabbrica Italiana Sintetici S.p.A., Famar Health Care Services, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Gerresheimer AG, Grifols S.A., Hikal Ltd, Hovione, Jubilant Pharmova Limited, Lonza Group AG, Pfizer Inc., Porton Pharma Solutions Ltd., Recipharm AB, Samsung Biologics Co., Ltd., Siegfried AG, The Fareva Group, Thermo Fisher Scientific Inc., Vetter Pharma-Fertigung GmbH & Co. KG, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Contract Development & Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Service, market is studied across Biologics Manufacturing Services, Drug Development Services, Pharmaceutical Manufacturing Services, and Secondary Packaging Services. The Biologics Manufacturing Services is further studied across Biologics API Manufacturing Services and Biologics FDF Manufacturing Services. The Pharmaceutical Manufacturing Services is further studied across Pharmaceutical API Manufacturing and Pharmaceutical FDF Manufacturing. The Pharmaceutical API Manufacturing is further studied across Capsule Manufacturing Services, Oral Liquid Manufacturing Services, Parenteral/Injectable Manufacturing Services, and Tablet Manufacturing Services.
  • Based on Development Stage, market is studied across Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials, Phase IV Clinical Trials, and Preclinical.
  • Based on End User, market is studied across Biotechnology Companies, Generic Pharmaceutical Companies, Pharmaceutical Companies, and Small & Mid-Size Pharma. The Pharmaceutical Companies is further studied across Big Pharma and Specialty Pharma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Demand for Generics and Biological Therapies
      • 5.1.1.2. Increasing Investments in Pharmaceutical R&D
      • 5.1.1.3. Increasing Number of CDMOs and Rising Investments in Advanced Manufacturing Technologies by CDMOs
    • 5.1.2. Restraints
      • 5.1.2.1. Introduction of Serialization
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing Focus on Nuclear Medicine and Specialty Drugs
      • 5.1.3.2. Growing need for Cell and Gene Therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Variable Trade Policies Between Countries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Service: Rising penetration of biologics manufacturing services by end-users to adhere to stringent regulatory standards
    • 5.2.2. End User: Big pharma companies widely adopting pharmaceutical CDMO services to manage complex drug development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pharmaceutical Contract Development & Manufacturing Market, by Service

  • 6.1. Introduction
  • 6.2. Biologics Manufacturing Services
    • 6.2.1. Biologics API Manufacturing Services
    • 6.2.2. Biologics FDF Manufacturing Services
  • 6.3. Drug Development Services
  • 6.4. Pharmaceutical Manufacturing Services
    • 6.4.1. Pharmaceutical API Manufacturing
      • 6.4.1.1. Capsule Manufacturing Services
      • 6.4.1.2. Oral Liquid Manufacturing Services
      • 6.4.1.3. Parenteral/Injectable Manufacturing Services
      • 6.4.1.4. Tablet Manufacturing Services
    • 6.4.2. Pharmaceutical FDF Manufacturing
  • 6.5. Secondary Packaging Services

7. Pharmaceutical Contract Development & Manufacturing Market, by Development Stage

  • 7.1. Introduction
  • 7.2. Phase I Clinical Trials
  • 7.3. Phase II Clinical Trials
  • 7.4. Phase III Clinical Trials
  • 7.5. Phase IV Clinical Trials
  • 7.6. Preclinical

8. Pharmaceutical Contract Development & Manufacturing Market, by End User

  • 8.1. Introduction
  • 8.2. Biotechnology Companies
  • 8.3. Generic Pharmaceutical Companies
  • 8.4. Pharmaceutical Companies
    • 8.4.1. Big Pharma
    • 8.4.2. Specialty Pharma
  • 8.5. Small & Mid-Size Pharma

9. Americas Pharmaceutical Contract Development & Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Pharmaceutical Contract Development & Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Pharmaceutical Contract Development & Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. AGC Biologics and BioConnection join forces to provide end-to-end biopharmaceutical development and manufacturing solutions, enhancing efficiency and speeding up market delivery.
    • 12.3.2. Kuhne Holding AG acquires majority stake in Aenova Group from BC Partners, leveraging resources for enhanced growth and innovation
    • 12.3.3. Alcami Announces Acquisition of West-Coast-Based Pacific Pharmaceutical Services
    • 12.3.4. Piramal Pharma to Invest INR 1,000 Crore for Expansion
    • 12.3.5. eXmoor Pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Acino International AG
  • 3. Aenova Holding GmbH
  • 4. Akums Drugs& Pharmaceuticals Ltd
  • 5. Almac Group Limited
  • 6. Aurobindo Pharma Limited
  • 7. Boehringer Ingelheim International GmbH
  • 8. Cambrex Corporation
  • 9. Catalent, Inc.
  • 10. Curia Global, Inc.
  • 11. Danaher Corporation
  • 12. Delwis Healthcare Pvt. Ltd.
  • 13. Evonik Industries AG
  • 14. Fabbrica Italiana Sintetici S.p.A.
  • 15. Famar Health Care Services
  • 16. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 17. Gerresheimer AG
  • 18. Grifols S.A.
  • 19. Hikal Ltd
  • 20. Hovione
  • 21. Jubilant Pharmova Limited
  • 22. Lonza Group AG
  • 23. Pfizer Inc.
  • 24. Porton Pharma Solutions Ltd.
  • 25. Recipharm AB
  • 26. Samsung Biologics Co., Ltd.
  • 27. Siegfried AG
  • 28. The Fareva Group
  • 29. Thermo Fisher Scientific Inc.
  • 30. Vetter Pharma-Fertigung GmbH & Co. KG
  • 31. WuXi Biologics Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CAPSULE MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY ORAL LIQUID MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PARENTERAL/INJECTABLE MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TABLET MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL FDF MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE I CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE II CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE IV CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIG PHARMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SPECIALTY PHARMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SMALL & MID-SIZE PHARMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 241.